We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
39 hedge funds and large institutions have $107M invested in Dianthus Therapeutics in 2023 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
30% more funds holding
Funds holding: 30 → 39 (+9)
1.43% more ownership
Funds ownership: 68.01% → 69.44% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less capital invested
Capital invested by funds: $136M → $107M (-$29.8M)
Holders
39
Holders Change
+9
Holders Change %
+30%
% of All Funds
0.57%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
10
Increased
10
Reduced
7
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$817K |
| 2 |
FAM
Fred Alger Management
New York
|
+$451K |
| 3 |
Millennium Management
New York
|
+$375K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$317K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$296K |
